Gary Nachman
Stock Analyst at Raymond James
(3.00)
# 1,312
Out of 5,147 analysts
97
Total ratings
58.9%
Success rate
6.28%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Reiterates: Strong Buy | $85 → $89 | $81.15 | +9.67% | 4 | Oct 30, 2025 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $18.30 | +3.83% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $13.49 | +270.64% | 3 | Oct 20, 2025 | |
| ABBV AbbVie | Reiterates: Outperform | $236 → $250 | $232.08 | +7.72% | 17 | Oct 17, 2025 | |
| AMGN Amgen | Assumes: Market Perform | n/a | $388.16 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.58 | +675.19% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $12.06 | +132.17% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $332.92 | -10.49% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $4.56 | +338.60% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $21.91 | +68.87% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $44.27 | -32.23% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $4.00 | +75.00% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $190.02 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $13.81 | -71.04% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $12.56 | +138.85% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $3.61 | +786.43% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $14.93 | -6.23% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $33.86 | -70.47% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $34.74 | -13.64% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $4.25 | +17,547.06% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $5.93 | +34.91% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $20.23 | +3.81% | 5 | May 11, 2020 |
Ionis Pharmaceuticals
Oct 30, 2025
Reiterates: Strong Buy
Price Target: $85 → $89
Current: $81.15
Upside: +9.67%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $18.30
Upside: +3.83%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $13.49
Upside: +270.64%
AbbVie
Oct 17, 2025
Reiterates: Outperform
Price Target: $236 → $250
Current: $232.08
Upside: +7.72%
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $388.16
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.58
Upside: +675.19%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $12.06
Upside: +132.17%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $332.92
Upside: -10.49%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $4.56
Upside: +338.60%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $21.91
Upside: +68.87%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $44.27
Upside: -32.23%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.00
Upside: +75.00%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $190.02
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $13.81
Upside: -71.04%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $12.56
Upside: +138.85%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.61
Upside: +786.43%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $14.93
Upside: -6.23%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $33.86
Upside: -70.47%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $34.74
Upside: -13.64%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.25
Upside: +17,547.06%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $5.93
Upside: +34.91%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $20.23
Upside: +3.81%